Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed We conducted a phase I dose-escalation and expansion study of azacitidine, venetoclax, and revumenib at two dose levels (113 mg or 163 mg orally every 12 hours in combination with strong cytochrome P450 inhibitor azoles) in patients aged 60 years and older newly diagnosed with AML with NPM1m or KMT2Ar (ClinicalTrials gov identifier: NCT03013998)
How I treat patients with AML using azacitidine and venetoclax This article casts a clinical spotlight on important challenges and dilemmas encountered in practice We also outline a structured framework to assist in the safe management of AZA-VEN in the clinic
Venetoclax (Venclexta®) + Azacitadine - AML | ChemoExperts Venetoclax is a targeted therapy designed to kill leukemia cells by binding to and inhibiting a protein in cancerous cells that prevents the cell from dying known as “BCL-2” When azacitidine and venetoclax are given together they work together better than if either drug is given alone
Venetoclax and azacitidine compared with induction chemotherapy for . . . Venetoclax (ven) plus azacitidine (aza) is the standard of care for patients with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy (IC) Some patients who are IC candidates instead receive ven aza
AML-454 Real-World Use of Azacitidine (AZA) and Venetoclax (VEN) in . . . Azacytidine and venetoclax combination regimen (AZA VEN) is the standard of care in AML settings for unfit to intensive chemotherapy patients However, AZA VEN is associated with an increased hematological toxicity compared to AZA alone
The Aza Ven reshuffle | Blood | American Society of Hematology Mostly focusing on the most widely used version of this therapy, azacytidine + venetoclax (Aza Ven), this new work focuses on a comprehensive molecular analysis of the acute myeloid leukemia (AML) specimens collected at study entry
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and . . . Azacitidine plus venetoclax is a standard of care for patients with newly diagnosed AML who are unfit for intensive chemotherapy However, FLT3 mutations are a common mechanism of resistance to this regimen The addition of gilteritinib, an oral FLT3 inhibitor, to azacitidine and venetoclax may improve outcomes in patients with FLT3 -mutated AML